Cargando…
Recognition and Accommodation at the Androgen Receptor Coactivator Binding Interface
Prostate cancer is a leading killer of men in the industrialized world. Underlying this disease is the aberrant action of the androgen receptor (AR). AR is distinguished from other nuclear receptors in that after hormone binding, it preferentially responds to a specialized set of coactivators bearin...
Autores principales: | Hur, Eugene, Pfaff, Samuel J, Payne, E. Sturgis, Grøn, Hanne, Buehrer, Benjamin M, Fletterick, Robert J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC509409/ https://www.ncbi.nlm.nih.gov/pubmed/15328534 http://dx.doi.org/10.1371/journal.pbio.0020274 |
Ejemplares similares
-
Cyclin E as a Coactivator of the Androgen Receptor
por: Yamamoto, Ayako, et al.
Publicado: (2000) -
Flexibility of PCNA-Protein Interface Accommodates Differential Binding Partners
por: Pedley, Anthony M., et al.
Publicado: (2014) -
“True” Antiandrogens—Selective
Non-Ligand-Binding Pocket Disruptors of Androgen Receptor–Coactivator
Interactions: Novel Tools for Prostate Cancer
por: Caboni, Laura, et al.
Publicado: (2012) -
Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion
por: Peng, Yi, et al.
Publicado: (2010) -
BAP18 coactivates androgen receptor action and promotes prostate cancer progression
por: Sun, Shiying, et al.
Publicado: (2016)